1. Home
  2. ASC vs VOR Comparison

ASC vs VOR Comparison

Compare ASC & VOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

ASC

Ardmore Shipping Corporation

HOLD

Current Price

$15.47

Market Cap

508.7M

ML Signal

HOLD

Logo Vor Biopharma Inc.

VOR

Vor Biopharma Inc.

HOLD

Current Price

$14.97

Market Cap

755.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ASC
VOR
Founded
2010
2015
Country
Bermuda
United States
Employees
N/A
N/A
Industry
Marine Transportation
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
508.7M
755.7M
IPO Year
2013
2021

Fundamental Metrics

Financial Performance
Metric
ASC
VOR
Price
$15.47
$14.97
Analyst Decision
Strong Buy
Buy
Analyst Count
2
10
Target Price
$15.00
$45.33
AVG Volume (30 Days)
509.3K
1.3M
Earning Date
05-06-2026
05-13-2026
Dividend Yield
2.00%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$16.60
N/A
Revenue Growth
N/A
N/A
52 Week Low
$9.18
$0.13
52 Week High
$16.91
$49.95

Technical Indicators

Market Signals
Indicator
ASC
VOR
Relative Strength Index (RSI) 52.94 48.75
Support Level $14.91 $11.38
Resistance Level $15.98 $16.88
Average True Range (ATR) 0.49 1.57
MACD -0.03 -0.08
Stochastic Oscillator 47.37 21.95

Price Performance

Historical Comparison
ASC
VOR

About ASC Ardmore Shipping Corporation

Ardmore Shipping Corp provides seaborne transportation of petroleum products and chemicals world-wide to oil majors, national oil companies, oil and chemical traders, and chemical companies, with its modern, fuel-efficient fleet of mid-size product and chemical tankers. The Company operates its business in one operating segment, the transportation of refined petroleum products and chemicals.

About VOR Vor Biopharma Inc.

Vor Biopharma Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of autoimmune diseases. Its program, telitacicept, is a potential first- and best-in-class dual BAFF/APRIL inhibitor designed to suppress the signaling pathways that drive the maturation, proliferation, and survival of harmful B cells, including self-reactive B cells, thereby reducing autoantibody production and preventing downstream tissue damage.

Share on Social Networks: